But I threw together some thoughts in about 10 mins or so -- (probably 30 now with posting to this forum)Questions for KK tomorrow - at present I'm not planning to ask them - others are welcome to if they wish
Phase 2 GVHD
- Is there anyreason why patient’s treated aren’t being reported as a number,1st , 2nd, 3rd etc rather than as apercentage (about 5%).
- Has the treatmentarm to control arm ratio been fixed? (ie 40 to treatment arm 20 tocontrol for a 2 to 1 ration or 30 to treatment arm 30 to control fora 1 to 1 ratio).
If not why not?
Is there any chancethat Cynata will need to raise funds to complete phase 2 in GVHD –or have the expenses for that discretionary undertaking by themanagement team already been fully paid for?
Recruiting – whyspend money recruiting a person to look at partnerships when thesubstantive value adding data that partners would be interested in(results from clinical trials) is still being generated? Isn’t thatpremature? Isn't it unfair to put a new hire into the money at 29cents if trial results come in that lift CYP above that through no work (on those trials) by the new hire?
MSB as a competitor
If MSB is granted aBLA for GVHD – what impact does Kilian see that having on orphandrug designation funding in the US if any – for instance does hethink it would be deemed the same drug by the FDA?
Does MSB’s patentgranted November 2023 in the US – entitled Mesenchymal Stem CellsExpressing TNF-alpha receptors constitute a problem for Cynata?
In the advent ofpatent offices granting patents too broadly to competitors doesCynata have the funds or the skills in management to do anythingabout that?
------------
I won't ask those, yet, (I see the main game currently as taking place between MSB and the FDA over GvHD BLA or not sooner than sculptor results or CYP phase 2 results) - so others can have them for nothing if they want to ask tommorow
I do think shareholders should get Kilian on the record about GvHD stuff - but experience suggests they (except for pfeifer) they won't and I expect Kilian would prefer to keep things rubbery and non specific.
- Forums
- ASX - By Stock
- CYP
- Rough thoughts in questions - help yourselves
Rough thoughts in questions - help yourselves
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
27.5¢ |
Change
0.005(1.85%) |
Mkt cap ! $49.39M |
Open | High | Low | Value | Volume |
27.5¢ | 27.5¢ | 27.5¢ | $2.85K | 10.36K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 351 | 28.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.0¢ | 16165 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 351 | 0.280 |
1 | 10909 | 0.275 |
1 | 5681 | 0.270 |
2 | 105000 | 0.265 |
1 | 77000 | 0.260 |
Price($) | Vol. | No. |
---|---|---|
0.290 | 16165 | 3 |
0.295 | 3518 | 1 |
0.310 | 13257 | 2 |
0.325 | 15000 | 1 |
0.335 | 29140 | 1 |
Last trade - 10.37am 03/07/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO & MD
Anthony Noble
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online